中国临床药理学杂志

利妥昔单抗联合缬沙坦治疗慢性肾小球肾炎患者的临床研究

PDF下载

刘倩 ^1a , 鲁华 ^1a , 霍鹏飞 ^1b , 刘艳玲 ^1b

中国临床药理学杂志 | 临床与基础桥接研究 2025,41(7): 901-905

收起

中国临床药理学杂志 |临床与基础桥接研究 2025 , 41 (7) : 901 -905

利妥昔单抗联合缬沙坦治疗慢性肾小球肾炎患者的临床研究

全屏

刘倩^1a, 鲁华^1a, 霍鹏飞^1b, 刘艳玲^1b

作者信息

^1a.邢台市人民医院，肾脏内科，河北邢台 054000

^1b.邢台市人民医院，血液净化室，河北邢台 054000

通讯作者:

刘倩 MP: 13831946628 E-mail: qianl23167@163.com

作者简介:

刘倩（1984-），女，主任医师，主要从事肾小球疾病方向的临床诊疗工作

Clinical trial of rituximab combined with valsartan in the treatment of patients with chronic glomerulonephritis

Qian LIU^1a, Hua LU^1a, Peng-fei HUO^1b, Yan-ling LIU^1b

Affiliations

^1a.Department of Nephrology, Xingtai People’s Hospital, Xingtai 054000, Hebei Province, China

^1b.Blood Purification Room, Xingtai People’s Hospital, Xingtai 054000, Hebei Province, China

出版时间: 2025-04-17 doi: 10.13699/j.cnki.1001-6821.2025.07.001

文章导航

摘要

收起

目的

观察利妥昔单抗注射液联合缬沙坦胶囊治疗慢性肾小球肾炎患者的临床疗效及安全性。

方法

将慢性肾小球肾炎患者随机分为对照组和试验组。对照组给予缬沙坦胶囊每次80 mg，qd，口服；试验组在对照组治疗的基础上，联合利妥昔单抗每次1 000 mg，静脉输注，第1、15天各给药1次。2组患者均治疗12个月。比较2组患者的临床疗效、炎症指标、肾功能、疾病复发情况，以及安全性。

结果

试验组入组78例，脱落9例，最终有69例纳入统计分析；对照组入组79例，脱落8例，最终71例纳入统计分析。治疗后，试验组和对照组的总有效率分别为88.41%（61例/69例）和61.97%（44例/71例），在统计学上差异有统计学意义（P<0.05）。治疗后，试验组和对照组的白细胞介素-1水平分别为（73.88±9.91）和（86.47±10.27）pmol·L^-1，肿瘤坏死因子-α水平分别为（42.17±5.66）和（47.94±5.52）pg·mL^-1，干扰素-γ水平分别为（13.29±3.86）和（17.72±4.08）pg·mL^-1，肌酸酐水平分别为（82.17±12.23）和（87.89±10.21）μmol·L^-1，尿素氮水平分别为（4.66±1.26）和（5.71±1.65）mmol·L^-1，24 h尿蛋白定量分别为（3.55±1.12）和（4.69±1.57）g，复发率分别为1.64%和18.18%，在统计学上差异均有统计学意义（均P<0.05）。试验组的药物不良反应主要有感染、中性粒细胞减少、恶心呕吐和白细胞减少，对照组的药物不良反应主要有血管性水肿、恶心呕吐和中性粒细胞减少。试验组和对照组的总药物不良反应发生率分别为7.25%和4.23%，在统计学上差异无统计学意义（P>0.05）。

结论

利妥昔单抗注射液联合缬沙坦胶囊治疗慢性肾小球肾炎患者的临床疗效比单用缬沙坦胶囊更佳，且不增加药物不良反应的发生率。

关键词

利妥昔单抗注射液 / 缬沙坦胶囊 / 慢性肾小球肾炎 / 肾功能 / 安全性评价

Abstract

收起

Objective

To observe the clinical efficacy and safety of rituximab injection combined with valsartan capsules in the treatment of patients with chronic glomerulonephritis.

Methods

The patients with chronic glomerulonephritis were randomly divided into control group and treatment group. The control group was given valsartan capsules 80 mg each time, qd, orally; on the basis of control group, the treatment group was combined with rituximab 1 000 mg per time, intravenous infusion, once on the 1st and 15th day. Two groups were treated for 12 months. The clinical efficacy, inflammatory indexes, renal function, disease recurrence and safety were compared between two groups.

Results

Seventy-eight cases were enrolled in the treatment group, 9 cases were dropped out, and finally 69 cases were included in the statistical analysis; 79 cases were enrolled in the control group, 8 cases were dropped out, and finally 71 cases were included in the statistical analysis. After treatment, the total effective rates of treatment and control groups were 88.41% (61 cases/69 cases) and 61.97% (44 cases/71 cases), with significant difference (P<0.05). After treatment, the levels of interleukin-1 in the treatment and control groups were (73.88±9.91) and (86.47±10.27) pmol·L^-1, the levels of tumor necrosis factor-α were (42.17±5.66) and (47.94±5.52) pg·mL^-1, the levels of interferon-γ were (13.29±3.86) and (17.72±4.08) pg·mL^-1, the levels of creatinine were (82.17±12.23) and (87.89±10.21) μmol·L^-1, the levels of urea nitrogen were (4.66±1.26) and (5.71±1.65) mmol·L^-1, the 24-hour urinary protein quantifications were (3.55±1.12) and (4.69±1.57) g, the recurrence rates were 1.64% and 18.18%, and the differences were statistically significant (all P<0.05). The adverse drug reactions of treatment group were infection, neutropenia, nausea and vomiting, and leukopenia, while those in the control group were angioedema, nausea and vomiting, and neutropenia. The total incidences of adverse drug reactions in the treatment and control groups were 7.25% and 4.23%, without significant difference (P>0.05).

Conclusion

The clinical efficacy of rituximab injection combined with valsartan capsules in the treatment of patients with chronic glomerulonephritis is better than valsartan capsules alone, without increasing the incidence of adverse drug reactions.

Key words

rituximab injection / valsartan capsule / chronic glomerulonephritis / renal function / safety evaluation

引用本文

刘倩, 鲁华, 霍鹏飞, 刘艳玲. 利妥昔单抗联合缬沙坦治疗慢性肾小球肾炎患者的临床研究. 中国临床药理学杂志, 2025 , 41 (7) : 901 -905 . DOI: 10.13699/j.cnki.1001-6821.2025.07.001

Qian LIU, Hua LU, Peng-fei HUO, Yan-ling LIU. Clinical trial of rituximab combined with valsartan in the treatment of patients with chronic glomerulonephritis[J]. Chinese Journal of Clinical Pharmacology, 2025 , 41 (7) : 901 -905 . DOI: 10.13699/j.cnki.1001-6821.2025.07.001

基金

收起

河北省卫生健康委医学科学研究课题基金资助项目(20191696)
邢台市重点研发计划自筹基金资助项目(2022ZC109)

参考文献

收起

文献

收起

参考文献引证文献

排序方式：

2025年第41卷第7期

PDF下载

引用本文

BibTeX

文章信息

doi: 10.13699/j.cnki.1001-6821.2025.07.001

接收时间：2024-11-18
首发时间：2026-08-04
出版时间：2025-04-17

补充材料

相关文章

文章信息

作者

出版历史

收稿日期：2024-11-18

基金

河北省卫生健康委医学科学研究课题基金资助项目(20191696)

邢台市重点研发计划自筹基金资助项目(2022ZC109)

作者信息

^1a.邢台市人民医院，肾脏内科，河北邢台 054000

^1b.邢台市人民医院，血液净化室，河北邢台 054000

通讯作者:

刘倩 MP: 13831946628 E-mail: qianl23167@163.com

参考文献

分享链接

https://castjournals.cast.org.cn/joweb/zglcylxzz/CN/10.13699/j.cnki.1001-6821.2025.07.001

分享至

全文二维码

扫描看全文

引用本文

BibTeX

本文的引用情况

2种不同金属材料的力学参数

科 Family	属数 Number of genus	种数 Number of species	占总种数比例 Percentage of total species (%)	属 Genus	种数 Number of species	占总种数比例 Percentage of total species (%)
鹅膏菌科Amanitaceae	2	11	5.26	鹅膏菌属 Amanita	10	4.78
小菇科 Mycenaceae	2	12	5.74	丝盖伞属 Inocybe	5	2.39
多孔菌科 Polyporaceae	8	14	6.70	蜡蘑属 Laccaria	5	2.39
红菇科 Russulaceae	3	23	11.00	小皮伞属 Marasmius	6	2.87
				小菇属 Mycena	11	5.26
				光柄菇属 Pluteus	5	2.39
				红菇属 Russula	17	8.13
				栓菌属 Trametes	5	2.39

关闭全屏

BibTeX
EndNote
RefWorks
TxT